ProCE Banner Activity

All-Oral Arsenic Trioxide–Based Induction in Newly Diagnosed Acute Promyelocytic Leukemia

Conference Coverage

All-oral arsenic trioxide–based induction was well tolerated and highly effective in patients with newly diagnosed APL when using a risk-adapted strategy to minimize chemotherapy exposure.

Released: December 12, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.